Shares of Illumina, Inc. (NASDAQ:ILMN) ended Wednesday session in green amid volatile trading. The shares closed up +0.63 points or 0.35% at $180.98 with 662,283.00 shares getting traded. Post opening the session at $180.31, the shares hit an intraday low of $177.96 and an intraday high of $181.32 and the price vacillated in this range throughout the day. The company has a market cap of $26.81 billion and the numbers of outstanding shares have been calculated to be 146.60 million shares.
Illumina, Inc. (ILMN) on July 28, 2016 announced that Philip W. Schiller has joined the company’s Board of Directors. Schiller is currently Apple’s Senior Vice President of Worldwide Marketing and is a member of Apple’s executive team responsible for the company’s product marketing, developer relations, business marketing, education marketing, international marketing and App Store programs.
Since rejoining Apple in April 1997, Schiller has helped the company create and market some of the best-selling products in the world including the Mac, iPod, iTunes, iPhone, the App Store, Apple TV and the Apple Watch.
“Phil’s track record and global experience in bringing world-class products to market will help guide us as we continue to develop innovative new solutions for our customers,” said Francis deSouza, Illumina President and Chief Executive Officer. “His vision, integrity and passion are fully aligned with Illumina’s core values.”
Schiller has more than 30 years of marketing and management experience, including over 25 at Apple in various marketing positions; as the Vice President of Product Marketing at Macromedia, Inc. of San Francisco, Calif.; as the Director of Product Marketing at FirePower Systems, Inc. of Menlo Park, Calif.; as an Information Technology Manager at Nolan, Norton & Company of Lexington, Mass.; and as a Programmer and Systems Analyst at Massachusetts General Hospital in Boston. He graduated with a B.S. in biology from Boston College.
Shares of Medtronic PLC (NYSE:MDT) ended Wednesday session in green amid volatile trading. The shares closed up +0.07 points or 0.08% at $86.74 with 3.21 million shares getting traded. Post opening the session at $86.56, the shares hit an intraday low of $86.16 and an intraday high of $86.89 and the price vacillated in this range throughout the day. The company has a market cap of $119.81 billion and the numbers of outstanding shares have been calculated to be 1.38 billion shares.
Medtronic PLC (MDT) on Sept. 28, 2016 announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed® 670G system – the first Hybrid Closed Loop insulin delivery system approved anywhere in the world. Featuring the company`s most advanced algorithm – SmartGuard(TM) HCL – the system is the latest innovation in Medtronic`s phased approach toward developing a fully automated, closed loop system. Medtronic is committed to simplifying and improving diabetes management through the advancement of smart algorithms that achieve greater glucose control with reduced patient input. Through SmartGuard HCL, the system builds on Medtronic`s industry leading algorithms to offer therapy customization so patients and providers can choose from increasing levels of automation that best fit their diabetes management needs.
“With SmartGuard HCL, the ability to automate basal insulin dosing 24 hours a day is a much-anticipated advancement in the diabetes community for the profound impact it may have on managing diabetes – particularly for minimizing glucose variability and maximizing time in the target range,” said Richard M. Bergenstal, M.D., principal investigator of the pivotal study and executive director of the Park Nicollet International Diabetes Center in Minneapolis. “The data from the pivotal trial were compelling and I am confident that this therapy will be well-received by both the clinical and patient community.”
“This significant milestone represents an important step forward in the management of type 1 diabetes and will improve the quality of life for those living with this chronic disease,” said Derek Rapp, president and CEO of JDRF, the leading global organization funding type 1 diabetes research. “We are very encouraged by the speed in which this groundbreaking technology was approved by the FDA, and we are proud of the role JDRF played in achieving this exciting breakthrough. Medtronic and JDRF are committed to ensuring appropriate patient access to this therapy.”